Gualtieri C T
Dis Nerv Syst. 1977 May;38(5):368-75.
Although the FDA recommends imipramine hydrochloride (IMI) only for temporary relief of symptoms of enuresis nocturna (EN), the drug has been applied to a number of other pediatric situations, including the Hyperkinetic Syndrome (HS), childhood depression, somnambulism and pavor nocturnus, school phobia, petit mal epilepsy, allergies, autism, encorpresis and head-banging. We have reviewed the literature, with particular attention to the pharmacokinetics of IMI in children, and its putative mechanisms of action. The drug probably works through a number of different actions, and the futher delineation of these will be of considerable heuristic value. We review the toxic effects of IMI treatment and IMI poisoning in children, and the pediatric literature concerning other antidepressant drugs and lithium carbonate (Li).
尽管美国食品药品监督管理局（FDA）仅推荐盐酸丙咪嗪（IMI）用于暂时缓解夜尿症（EN）的症状，但该药物已被应用于许多其他儿科病症，包括多动综合征（HS）、儿童抑郁症、梦游症和夜惊、学校恐惧症、失神癫痫、过敏、自闭症、遗粪症和撞头行为。我们回顾了相关文献，特别关注了IMI在儿童体内的药代动力学及其假定的作用机制。该药物可能通过多种不同作用发挥功效，进一步阐明这些作用将具有相当大的启发价值。我们回顾了IMI治疗和儿童IMI中毒的毒性作用，以及有关其他抗抑郁药物和碳酸锂（Li）的儿科文献。
